Last reviewed · How we verify
sodium zirconium cyclic silicate
Sodium zirconium cyclic silicate is a non-absorbed potassium binder that traps potassium in the gastrointestinal tract through ion exchange, reducing serum potassium levels.
Sodium zirconium cyclic silicate is a potassium binder under investigation for managing hyperkalemia. It has shown promise in early clinical trials but lacks FDA approval. The drug is being studied for its impact on cardiac electrical stability and as an adjunct in pulpotomy techniques.
At a glance
| Generic name | sodium zirconium cyclic silicate |
|---|---|
| Also known as | hemodialysis |
| Sponsor | Peking University First Hospital |
| Drug class | Potassium binder |
| Target | Potassium ion (K+) in gastrointestinal lumen |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Cardiology |
| Phase | FDA-approved |
Mechanism of action
The drug is a microporous, inorganic compound that selectively binds potassium ions in the colon via a non-selective cation exchange mechanism. It does not require acidic conditions to function and works throughout the entire gastrointestinal tract. The potassium-bound complex is then eliminated in feces, effectively lowering serum potassium without systemic absorption.
Approved indications
- Hyperkalemia (elevated serum potassium levels)
Common side effects
- Constipation
- Nausea
- Abdominal discomfort
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sodium zirconium cyclic silicate CI brief — competitive landscape report
- sodium zirconium cyclic silicate updates RSS · CI watch RSS
- Peking University First Hospital portfolio CI